EUVIMEDEUVIMED entdecken
Crossref

Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods

William T Higgins, Sandip Vibhute, Chad Bennett, Steffen Lindert iD

Journal of Chemical Information and Modeling · 2024

DOI: 10.1021/acs.jcim.3c01358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, 2024. Verfasst von William T Higgins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio 43210, United States. Hauptthemen laut MEDLINE: Oxidoreductases Acting on CH-CH Group Donors, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We used a structure-based drug discovery approach to identify novel inhibitors of human dihydroorotate dehydrogenase (DHODH), which is a therapeutic target for treating cancer and autoimmune and inflammatory diseases. In the case of acute myeloid leukemia, no previously discovered DHODH inhibitors have yet succeeded in this clinical application. Thus, there remains a strong need for new inhibitors that could be used as alternatives to the current standard-of-care. Our goal was to identify novel inhibitors of DHODH. We implemented prefiltering steps to omit PAINS and Lipinski violators at the earliest stages of this project. This enriched compounds in the data set that had a higher potential of favorable oral druggability. Guided by Glide SP docking scores, we found 20 structurally unique compounds from the ChemBridge EXPRESS-pick library that inhibited DHODH with IC50, DHODH values between 91 nM and 2.7 μM. Ten of these compounds reduced MOLM-13 cell viability with IC50, MOLM-13 values between 2.3 and 50.6 μM. Compound 16 (IC50, DHODH = 91 nM) inhibited DHODH more potently than the known DHODH inhibitor, teriflunomide (IC50, DHODH = 130 nM), during biochemical characterizations and presented a promising scaffold for future hit-to-lead optimization efforts. Compound 17 (IC50, MOLM-13 = 2.3 μM) was most successful at reducing survival in MOLM-13 cell lines compared with our other hits. The discovered compounds represent excellent starting points for the development and optimization of novel DHODH inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oxidoreductases Acting on CH-CH Group DonorsNeoplasmsHumansDihydroorotate DehydrogenaseDrug DiscoveryEnzyme Inhibitors

Substanzen

Dihydroorotate DehydrogenaseOxidoreductases Acting on CH-CH Group DonorsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio 43210, United States.
  • Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, United States.
  • Drug Development Institute, Ohio State University, Columbus, Ohio 43210, United States.

ORCID-Profile: Steffen Lindert

Zitieren

APA

Higgins, W. T., Vibhute, S., Bennett, C., & Lindert, S. (2024). Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.3c01358

Vancouver

Higgins WT, Vibhute S, Bennett C, Lindert S. Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods. Journal of Chemical Information and Modeling. 2024. doi:10.1021/acs.jcim.3c01358

BibTeX
@article{Higgins2024,
  author = {Higgins, William T and Vibhute, Sandip and Bennett, Chad and Lindert, Steffen},
  title = {Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods},
  journal = {Journal of Chemical Information and Modeling},
  year = {2024},
  doi = {10.1021/acs.jcim.3c01358}
}
Kostenlos starten →